PDSB Stock Analysis: Buy, Sell, or Hold?
PDSB - PDS Biotechnology Corporation Common Stock
$0.20
-0.01 (-4.67%)
âŧ
5d:
-7.9%
30d:
-71.44%
90d:
-82.41%
WAIT
LOW Confidence
Analysis Updated: Sep 1, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When PDSB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: PDSB is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: PDSB is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: PDSB is currently trading at $0.20, which is considered slightly low relative to its 30-day fair value range of $0.20 to $0.69.
Technical Outlook: Technically, PDSB is in a strong downtrend. Immediate support is located at $0.20, while resistance sits at $0.24. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: PDSB scores 76/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $5.75 (+2718.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PDSB is in a strong downtrend. Immediate support is located at $0.20, while resistance sits at $0.24. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: PDSB scores 76/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $5.75 (+2718.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$0.20 -
$0.69
Company Quality Score
50/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
84.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (76/100)
- BEARISH: Downward momentum (-4.7%)
- BULLISH: Trading 2718.6% below Wall St target ($5.75)
- WARNING: Composite score 50/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.20 -
$0.69
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$0.20
Resistance Level
$0.24
Current Trend
Strong Downtrend
Technical data as of
Sep 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.55
Wall Street Target
$5.75
(+2718.6%)
Share & Embed Analysis
Last updated: September 02, 2026 3:05 AM ET
Data refreshes hourly during market hours. Next update: 4:05 AM
Data refreshes hourly during market hours. Next update: 4:05 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PDSB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$370 | 44 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 41 HOLD |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$563 | 35 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$313 | 48 HOLD |
|
APLS
Apellis Pharmaceuticals âĻ |
BUY
22 analysts |
$41 | 50 HOLD |
